Table 46.
Country | N | GEN | CHL | AMP | CTX | CAZ | MEM | TGC |
---|---|---|---|---|---|---|---|---|
Germany | 162 | 5.6 | 9.9 | 58 | 4.9 | 4.3 | 0 | 0 |
Italy | 170 | 4.1 | 32.4 | 80.6 | 4.1 | 2.9 | 0 | 0 |
Netherlands | 134 | 2.2 | 3.7 | 28.4 | 2.2 | 1.5 | 0 | 0 |
Total (3 MSs) | 466 | 4.1 | 16.3 | 57.7 | 3.9 | 3 | 0 | 0 |
Country | N | NAL | CIP | AZM | COL | SMX | TMP | TET |
---|---|---|---|---|---|---|---|---|
Germany | 162 | 45.1 | 50 | 1.2 | 4.3 | 46.3 | 35.8 | 33.3 |
Italy | 170 | 60 | 64.7 | 4.1 | 5.9 | 66.5 | 54.7 | 65.9 |
Netherlands | 134 | 20.9 | 22.4 | 0 | 0.7 | 20.9 | 17.2 | 26.1 |
Total (3 MSs) | 466 | 43.6 | 47.4 | 1.9 | 3.9 | 46.4 | 37.3 | 43.1 |
ECOFFs: epidemiological cut‐off values; MSs: Member States; N: number of isolates tested; GEN: gentamicin; CHL: chloramphenicol; AMP: ampicillin; CTX: cefotaxime; CAZ: Ceftazidime; MEM: meropenem; TGC: tigecycline; NAL: nalidixic acid; CIP: ciprofloxacin; AZM: azithromycin; COL: colistin; SMX: sulfamethoxazole; TMP: trimethoprim; TET: tetracycline.